Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study

Journal of the American Academy of Dermatology

Volumn 51, Issue 5, 2004, Pages 731-738

  Gribetz, Carin ^a   Ling, Mark ^b   Lebwohl, Mark ^a   Pariser, David ^c   Draelos, Zoe ^d   Gottlieb, Alice B ^e   Zaias, Nardo ^f   Chen, Diana M ^g   Parneix Spake, Anne ^h   Hultsch, Thomas ^h   Menter, Alan ⁱ  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MedaPhase Inc   (United States)

^c Eastern Virginia School of Medicine   (United States)

^d DERMATOLOGY CONSULTING SERVICES   (United States)

^e UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^f MOUNT SINAI MEDICAL CENTER   (United States)

^g ABBOTT LABORATORIES   (United States)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIPSORIASIS AGENT; PIMECROLIMUS;

ADULT; AGED; ARTICLE; BACTERIAL SKIN DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DERMATOMYCOSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PSORIASIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SKIN ATROPHY; TELANGIECTASIA; TOPICAL TREATMENT;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PSORIASIS; TACROLIMUS; TREATMENT OUTCOME;

EID: 8744304117     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2004.06.010     Document Type: Article

References (28)

1. G. Krueger, J. Koo, M. Lebwohl, A. Menter, R.S. Stern, and T. Rolstad The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey Arch Dermatol 137 2001 280 284
2. M.G. Lebwohl W.R. Heymann J. Berth-Jones I. Coulson Treatment of skin disease: comprehensive therapeutic strategies 2002 Mosby St Louis
3. P. Van de Kerkoff Papulosquamous and eczematous dermatoses: psoriasis J.L. Bologna J.L. Jorizzo R.P. Rapini Dermatology 2003 Mosby St Louis 125 149
4. C.M. Mills, and R. Marks Side effects of topical glucocorticoids Curr Probl Dermatol 21 1993 122 131
5. D. Murdoch, and S.P. Clissold Calcipotriol: a review of its pharmacological properties and therapeutic use in psoriasis vulgaris Drugs 43 1992 415 429
6. K. Kragballe Treatment of psoriasis with calcipotriol and other vitamin D analogues J Am Acad Dermatol 27 1992 1001 1008
7. A. Stuetz, M. Grassberger, and J.G. Meingassner Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity Semin Cutan Med Surg 20 2001 233 241
8. J.G. Meingassner, M. Grassberger, H. Fahrngruber, H.D. Moore, H. Schuurman, and A. Stutz A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology Br J Dermatol 137 1997 568 576
9. U. Mrowietz, M. Graeber, M. Brautigam, M. Thurston, A. Wagenaar, and G. Weidinger The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion Br J Dermatol 139 1998 992 996
10. K. Rappersberger, M. Komar, M.E. Ebelin, G. Scott, P. Burtin, and G. Greig Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated J Invest Dermatol 119 2002 876 887
11. V.C. Ho, A. Gupta, R. Kaufmann, G. Todd, F. Vanaclocha, and R. Takaoka Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants J Pediatr 142 2003 155 162
12. A. Kapp, K. Papp, A. Bingham, R. Folster-Holst, J.P. Ortonne, and P.C. Potter Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug J Allergy Clin Immunol 110 2002 277 284
13. U. Wahn, J.D. Bos, M. Goodfield, R. Caputo, K. Papp, and A. Manjra Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children Pediatrics 110 2002 e2
14. L.F. Eichenfield, A.W. Lucky, M. Boguniewicz, R.G. Langley, R. Cherill, and K. Marshall Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents J Am Acad Dermatol 46 2002 495 504
15. M. Meurer, R. Folster-Holst, G. Wozel, G. Weidinger, M. Junger, and M. Brautigam Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study Dermatology 205 2002 271 277
16. C. Queille-Roussel, C. Paul, L. Duteil, M.C. Lefebvre, G. Rapatz, and M. Zagula The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study Br J Dermatol 144 2001 507 513
17. C. Robert, and T.S. Kupper Inflammatory skin diseases, T cells and immune surveillance N Engl J Med 341 1999 1817 1828
18. E. Christophers The immunopathology of psoriasis Int Arch Allergy Immunol 110 1996 199 206
19. J.C. Prinz The role of T cells in psoriasis J Eur Acad Dermatol Venereol 17 2003 257 270
20. J.G. Krueger The immunologic basis for the treatment of psoriasis with new biologic agents J Am Acad Dermatol 46 2002 1 23
21. R.B. Stoughton, and R.C. Cornell Corticosteroids T.B. Fitzpatrick A.Z. Eisen K. Wolff I.M. Freedberg K.F. Austen Dermatology in general medicine 1971 McGraw-Hill New York
22. C. Queille-Roussel, M. Graeber, M. Thurston, J.M. Lachapelle, J. Decroix, and C. De Cuyper SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge Contact Dermatitis 42 2000 349 350
23. C.E. Crutchfield III Pimecrolimus: a new treatment for seborrheic dermatitis Cutis 70 2002 207 208
24. I. Brownell, L.T. Quan, and S. Hsu Topical pimecrolimus in the treatment of seborrheic dermatitis Dermatol Online J 9 2003 13
25. F.A. Mayoral, C. Gonzales, N.S. Shah, and C. Arciniegas Repigmentation of vitiligo with pimecrolimus cream: a case report Dermatology 207 2003 322 323
26. S. Kienbaum, P. Lehmann, and T. Ruzicka Topical calcipotriol in the treatment of intertriginous psoriasis Br J Dermatol 135 1996 647 650
27. M.G. Lebwohl, M.H. Tan, S.L. Meador, and G. Singer Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas J Am Acad Dermatol 44 2001 77 82
28. A.K. Freeman, G.J. Linowski, C. Brady, L. Lind, P. VanVeldhuisen, and G. Singer Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas J Am Acad Dermatol 48 2003 564 568